Scopus BioPharma Inc. (SCPS)
OTCMKTS · Delayed Price · Currency is USD
0.0003
0.00 (0.00%)
Jan 21, 2025, 3:00 PM EST

Scopus BioPharma Company Description

Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs.

It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses.

The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein.

Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem.

The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017.

Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.

Scopus BioPharma Inc.
Scopus BioPharma logo
Country United States
Founded 2017
Industry Biotechnology
Sector Healthcare
Employees 13

Contact Details

Address:
420 Lexington Avenue
New York, Delaware 10170
United States
Phone 212 479 2513
Website scopusbiopharma.com

Stock Details

Ticker Symbol SCPS
Exchange OTCMKTS
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
ISIN Number US8091711015
SIC Code 2836

Key Executives

Name Position
Dr. Alan D. Horsager Ph.D. President?of?Immuno-Oncology and President and Chief Executive Officer of Duet BioTherapeutics
Ira Scott Greenspan Senior Advisor and Director
Robert J. Gibson Vice Chairman, Secretary and Treasurer